{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Table 9.1', 'Restricted Medications and Therapies', 'Medication/Therapy', 'Restricted Dose or Time Period', 'Orbital irradiation for TED', 'Any history or planned procedure during entire study', 'duration through Week 48 of Follow-Up Period.', 'Eye surgery for TED', 'Any history or planned procedure during entire study', 'duration through Week 48 of Follow-Up Period.', 'Steroids for treatment of TED', 'Steroids (IV or oral) for treatment of TED and steroid eye', 'drops are not allowed between Week 24 of the HZNP-TEP-', '301 protocol and Baseline/Day 1 of the HZNP-TEP-302', 'protocol through the end of study visit.', 'Steroids for conditions other than TED', 'Systemic steroid use (IV or oral) for conditions other than', 'TED is not allowed during the study however topical', 'steroids for dermatological conditions, inhaled steroids, and', 'IV dexamethasone for infusion-associated AEs are allowed.', 'Non-steroid eye drops', 'Vasoconstrictor eye drops are not allowed during the study.', 'Other non-steroid drops such as saline or methylcellulose are', 'allowed but should not be used on the day of a clinic visit.', 'Selenium or biotin for TED', 'Selenium or biotin for TED is not allowed during the study.', 'A multivitamin (taken maximally once daily) containing', 'selenium and/or biotin is allowed.', 'Rituximab (Rituxan\u00b0 R or MabThera\u00ae) or', 'Any previous use or anticipated use during the study.', 'tocilizumab (Actemra or Roactemra)', 'Non-steroid immunosuppressive agent (other than', 'Use of a non-steroid immunosuppressive agent is not', 'rituximab or tocilizumab)', 'allowed during the study.', 'Investigational agent', '60 days prior to study entry through study completion.', 'Illicit drug/alcohol use', 'History of abuse within the past 2 years or abuse during', 'study.', 'Hearing loss and/or ototoxicity is not considered to be an adverse event causally associated with', 'the use of teprotumumab. However, it may be reasonable to avoid ototoxic medications such as', 'systemic administration of aminoglycoside and platinum-based chemotherapy during the study.', 'The following medications may cause muscle spasm/cramps and should be avoided during the', 'study: donepezil, neostigmine, and vincristine.', 'All concomitant treatment (for TED and other conditions) in the Treatment Period and the', 'Follow-Up Period must be documented in the eCRF.', '9.4.10 Treatment Compliance', 'The Investigator is responsible for ensuring that dosing is administered in compliance with the', 'protocol. Delegation of this task must be clearly documented and approved by the Investigator.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 81 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'All infusions of study medication will be administered at the clinic under the supervision of', 'clinic staff. Infusion volumes, and start and stop times of the infusions will be recorded in the', 'eCRF.', 'An inventory of the study medication supplies will be performed by the site or authorized study', \"designee and recorded onto the Drug Accountability Log in the subject's source document\", 'records or equivalent.', '9.5', 'Efficacy, Quality-of-Life, Pharmacokinetic, and Safety Variables', 'The Schedule of Assessments was previously provided in Section 2.1.', '9.5.1 Efficacy Variables', 'Efficacy assessments will be performed for both eyes at each assessment time point. The \"study', 'eye\" (i.e., most severely affected eye) will remain the same as that identified at the Baseline', '(Day 1) Visit of Study HZNP-TEP-301. Both eyes will be assessed for efficacy but the study eye', 'will be used to assess the primary outcome measure.', 'Efficacy will be assessed by proptosis (measured as exophthalmos evaluation of the Clinical', 'Measures of Severity using a Hertel instrument provided by the Sponsor for consistency in', 'measurement), CAS (7-item scale), diplopia (measured as part of the Clinical Measures of', 'Severity) and Clinical Measures of Severity (including motility restriction assessments).', '9.5.1.1 Proptosis (Exophthalmos)', 'Proptosis assessments will be performed using a Hertel exophthalmometer provided by the', 'Sponsor for consistency in measurement, and (except when strictly unavoidable) the same Hertel', 'instrument and same observer should be used at each evaluation for the full duration of the study.', 'Additionally, the same intercanthal distance (ICD) must be used on each occasion. Instructions', 'for the measurement of proptosis are included in Section 17.2.', 'Proptosis will be measured for each eye on Day 1 and Weeks 6, 12, 18, and 24 (or premature', 'withdrawal [PW]) during the Treatment Period, and at Months 7, ,9, and 12 (or PW) during the', 'Follow-Up Period. Measurements will be recorded on the Clinical Measures of Severity eCRF', 'under exophthalmos.', '9.5.1.2 Clinical Activity Score (CAS)', 'The CAS will be completed on Day 1 and Weeks 6, 12, 18, and 24 (or PW) during the Treatment', 'Period, and at Months 7, ,9, and 12 (or PW) during the Follow-Up Period using the 7-item', \"European Group on Graves' Ophthalmopathy (EUGOGO) amended CAS [Mourits et al, 1989]\", '(Table 9.2).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 82 of 118']\n\n###\n\n", "completion": "END"}